A Two-Part First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Oral Doses of GSK3884464 in a Randomized, Double Blind, Placebo-Controlled, Dose Escalation Study in Healthy Participants
Latest Information Update: 09 May 2024
At a glance
- Drugs GSK 3884464 (Primary)
- Indications Heart failure
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 16 Aug 2023 Status changed from recruiting to discontinued to allow for additional assessments from supplementary non-clinical activities.
- 04 Nov 2022 Planned End Date changed from 20 Feb 2023 to 23 Nov 2023.
- 04 Nov 2022 Planned primary completion date changed from 20 Feb 2023 to 23 Nov 2023.